Patterns of Response in Patients with Pretreated Metastatic Melanoma who Received Ipilimumab 3 mg/kg in a European Expanded Access Program: Five Illustrative Case Reports

Ipilimumab 3 mg/kg was the first agent to improve survival of pretreated advanced melanoma patients. Nonconventional response patterns to ipilimumab have been reported widely, but most of these data were from studies with ipilimumab 10 mg/kg. Here, case reports from five patients treated within an e...

Full description

Saved in:
Bibliographic Details
Main Authors: Wilgenhof, Sofie, Four, Stephanie Du, Everaert, Hendrik, Neyns, Bart
Format: Artigo
Language:Inglês
Published: Informa Healthcare 2012
Subjects:
Original Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3536036/
https://ncbi.nlm.nih.gov/pubmed/23043499
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/07357907.2012.727934
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items